Overview

Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis

Status:
Terminated
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore immunomodulatory and immunosuppressive mechanisms of action of fingolimod in patients with Relapsing remitting multiple Sclerosis to collect data on biomarkers after initiation of fingolimod treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Heinrich-Heine University, Duesseldorf
Collaborator:
Novartis Pharmaceuticals
Treatments:
Fingolimod Hydrochloride